Reviews in Endocrine and Metabolic Disorders, Год журнала: 2023, Номер 25(1), С. 109 - 121
Опубликована: Июнь 29, 2023
Язык: Английский
Cancers, Год журнала: 2021, Номер 13(21), С. 5567 - 5567
Опубликована: Ноя. 7, 2021
Over the last few years, a great advance has been made in comprehension of molecular pathogenesis underlying thyroid cancer progression, particularly for papillary (PTC), which represents most common malignancy. Putative driver mutations have identified more than 98% PTC, and new PTC classification into subtypes proposed order to resolve clinical uncertainties still present management patients. Additionally, prognostic stratification systems profoundly modified over decade, with view refine patients' staging being able choose approach tailored on single patient's needs. Here, we will briefly discuss recent changes nodules, review current patients by analyzing promising clinicopathological features (i.e., gender, auto-immunity, multifocality, histological variants, vascular invasion) as well markers BRAF/TERT promoter mutations, miRNAs, components plasminogen activating system) potentially capable ameliorating prognosis
Язык: Английский
Процитировано
84
The Journal of Clinical Endocrinology & Metabolism, Год журнала: 2023, Номер 108(11), С. 2999 - 3008
Опубликована: Апрель 18, 2023
Abstract Context Comprehensive genomic analysis of thyroid nodules for multiple classes molecular alterations detected in a large series fine needle aspiration (FNA) samples has not been reported. Objective To determine the prevalence clinically relevant Bethesda categories III-VI (BCIII-VI) nodules. Methods This retrospective FNA samples, tested by ThyroSeq v3 using Genomic Classifier and Cancer Risk at UPMC Molecular Pathology laboratory, analyzed diagnostic, prognostic, targetable genetic total 50 734 BCIII-VI from 48 225 patients. Results Among informative 65.3% were test-negative, 33.9% positive, 0.2% positive medullary carcinoma, 0.6% parathyroid. The benign call rate BCIII-IV was 68%. test-positive 73.3% had mutations, 11.3% gene fusions, 10.8% isolated copy number alterations. Comparing with BCV-VI revealed shift predominantly RAS-like to BRAF V600E-like fusions involving receptor tyrosine kinases (RTK). Using Classifier, high-risk profile, which typically included TERT or TP53 found 6% more frequently BCV-VI. RNA-Seq confirmed detection novel RTK 98.9% cases. Conclusion In this series, 68% classified as negative ThyroSeq, potentially preventing diagnostic surgery subset Specific most nodules, higher mutations compared offering prognostic therapeutic information patient management.
Язык: Английский
Процитировано
31
International Journal of Molecular Sciences, Год журнала: 2021, Номер 22(21), С. 11829 - 11829
Опубликована: Окт. 31, 2021
Thyroid cancers (TCs) are the most common tumors of endocrine system and a constant rise in number TC cases has been observed for past few decades. TCs one frequent younger adults, especially women, therefore early diagnosis effective therapy important. Ultrasonography examination followed by fine needle biopsy have become gold standard TCs, as these strategies allow early-stage detection aid accurate qualification further procedures, including surgical treatment. Despite all advancements treatment mortality levels still observed. Therefore, novel generation line targeted is being developed, personalized therapies with kinase inhibitors. Recent molecular studies on demonstrate that inhibitor-based might be considered promising. In decade, new inhibitors different mechanisms action reported approved clinical trials. This review presents an up-to-date picture approaches challenges focusing latest findings over two years.
Язык: Английский
Процитировано
36
Cells, Год журнала: 2023, Номер 12(2), С. 274 - 274
Опубликована: Янв. 10, 2023
Papillary thyroid cancer (PTC) is the most prevalent histological type of (TC) worldwide. Although tumor metastasis occurs in regional lymph nodes, distant (DM) may also occur. Radioactive iodine (RAI) therapy an effective treatment for TC; however, resistance to RAI patients with DM. Therefore, this study, we investigated efficacy DM-related biomarkers as therapeutic targets PTC therapy. ABCA1 expression was higher aggressive BCPAP cells than other terms migration and invasion capacity. The knockdown
Язык: Английский
Процитировано
13
Frontiers in Endocrinology, Год журнала: 2022, Номер 13
Опубликована: Март 1, 2022
Background Follicular thyroid cancer (FTC) is the second most common malignancy of thyroid. About 7%–23% patients with FTC have distant metastasis. The aim this study was to investigate risk factors associated metastasis and impact on survival in patients. Methods Patients were analyzed using a prospectively maintained dataset registered at tertiary hospital Taiwan between December 1976 May 2020. Results A total 190 mean follow-up 7.7 years included study, including 29 diagnosis, 14 who developed during follow-up, 147 without Multivariate analysis adjusted for age, gender, tumor stage, extrathyroidal invasion revealed old age (≥ 55 years) (adjusted odds ratio, 27.6; 95% confidence interval [CI], 8.75–86.8; P < 0.001) (odds 24.1; CI, 3.50–166.5; = significantly an increased Metastasis correlated higher cancer-specific mortality hazard 35.5; 6.1–206.1; 0.001). In addition, metastatic diagnosed initial presentation had lowest 10-year rate (26.0%), followed by those disease after treatment (76.6%), while all alive (100%) (P ≤ 0.002 comparisons). Conclusions Age are significant FTC. FTC, especially when presentation, dismal outcomes.
Язык: Английский
Процитировано
22
Frontiers in Endocrinology, Год журнала: 2022, Номер 13
Опубликована: Июль 8, 2022
Thyroid cancer (TC) is the most common endocrine malignancy. TC classified as differentiated (DTC), which includes papillary and follicular subtypes Hürthle cell variants, medullary (MTC), anaplastic (ATC), poorly (PDTC). The standard of care in DTC consists surgery together with radioactive iodine ( 131 I) therapy thyroid hormone, but patients MTC do not benefit from I therapy. Patients advanced resistant to treatment (RAI-R) have no chance cure, well affected by ATC progressive MTC, conventional plays only a palliative role, representing, until few years ago, an urgent unmet need. In last decade, better understanding molecular pathways involved tumorigenesis specific histopathological has led develop tyrosine kinase inhibitors (TKIs). TKIs represent valid disease were tested all TC, highlighting need improve progression-free survival. However, treatments using these novel therapeutics are often accompanied side effects that required optimal management minimize their toxicities thereby enable who show continue obtain maximal clinical efficacy. goal this overview provide update on current use main drugs recently studied for adverse events.
Язык: Английский
Процитировано
21
The Journal of Clinical Endocrinology & Metabolism, Год журнала: 2023, Номер 108(11), С. 2759 - 2771
Опубликована: Май 18, 2023
Abstract Over the past 3 decades, advances in molecular genetics of thyroid cancer (TC) have been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main drivers differentiated TC pathogenesis are single-point mutations gene fusions components Mitogen-activated protein kinase (MAPK) phosphoinositide-3-kinase-protein B/Akt (PI3K/Akt) pathways. Other important genetic alterations more advanced types include TERT promoter, TP53, EIF1AX, epigenetic alterations. Using this knowledge, several tests developed for cytologically indeterminate nodules. Currently, commercially available use including a DNA/RNA-based test (ThyroSeq v.3), an RNA-based (Afirma Gene Sequencing Classifier), hybrid DNA/miRNA test, ThyGeNEXT/ThyraMIR. These mostly used to rule out malignancy Bethesda III IV nodules because they all high sensitivities negative predictive values. Their common use, predominantly United States, has resulted significant reduction unnecessary surgeries benign Some these also provide information on underlying TC; may support decision making initial management planning, although practice not yet widely adopted. More importantly, testing is essential patients with disease before using specific mono-kinase inhibitors (eg, selpercatinib RET-altered TC) drugs ineffective absence target. This mini-review discusses utilization data clinical different situations.
Язык: Английский
Процитировано
12
Heliyon, Год журнала: 2024, Номер 10(11), С. e31876 - e31876
Опубликована: Май 25, 2024
Thyroid cancer (TC) is the most common malignant tumor in endocrine system, also one of head and neck tumor. Follicular Carcinoma (FTC) plays an important role pathological classification thyroid cancer. This study aimed to develop innovative predictive tool, a nomogram, for predicting specific survival (CSS) middle-aged FTC patients.
Язык: Английский
Процитировано
4
Endocrine Practice, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 163 - 193
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0